Kevin J. Hamblett, Ph.D.
Affiliations: | 2002 | University of Washington, Seattle, Seattle, WA |
Area:
Biomedical Engineering, Pharmacy, Radiology, OncologyGoogle:
"Kevin Hamblett"Parents
Sign in to add mentor| Patrick S. Stayton | grad student | 2002 | University of Washington | |
| (Optimization of pretargeted radioimmunotherapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hamblett KJ, Le T, Rock BM, et al. (2016) Altering antibody drug conjugate binding to the Neonatal Fc Receptor impacts efficacy and tolerability. Molecular Pharmaceutics |
| Hamblett KJ, Kozlosky CJ, Siu S, et al. (2015) AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Molecular Cancer Therapeutics. 14: 1614-24 |
| McDonagh CF, Turcott E, Westendorf L, et al. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Engineering, Design & Selection : Peds. 19: 299-307 |
| Sun MM, Beam KS, Cerveny CG, et al. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chemistry. 16: 1282-90 |
| Hamblett KJ, Press OW, Meyer DL, et al. (2005) Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. Bioconjugate Chemistry. 16: 131-8 |
| Hamblett KJ, Barton J, Cerveny CG, et al. (2005) SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30+ Malignancies. Blood. 106: 610-610 |
| Hamblett KJ, Kegley BB, Hamlin DK, et al. (2002) A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjugate Chemistry. 13: 588-98 |